Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response study of recombinant Timothy grass pollen allergen immunotherapy in allergic rhinitis/rhinoconjunctivitis
2007-002808-18Phase 2Completed
- Sponsor
- Allergopharma
- Start
- Jul 2007
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Phleum pratense major allergens adsorbed onto aluminium hydroxide in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (5 arms), sponsored by Allergopharma. Primary endpoint: Systemic reaction rate. Started Jul 2007; status: completed.
02
Drugs
Phleum pratense major allergens adsorbed onto aluminium hydroxide
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2007-002808-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002808-18.